Back to search results

Observational Study for Vincristine-Induced Peripheral Neuropathy (VIPN)

This study is looking for children and adolescents aged 6 to 18 who are receiving vincristine chemotherapy. The goal is to develop a new, easy-to-use technology to objectively measure vincristine-induced peripheral neuropathy (VIPN), a type of nerve damage caused by the medication. This technology could help doctors better monitor VIPN, even before symptoms appear, which might allow them to adjust vincristine doses to maximize treatment effectiveness while minimizing long-term side effects. It could also help in developing new treatments for VIPN. The study aims to characterize a neuropathy index using this new technology, with measurements taken at 1 year. This is an observational study, meaning there are no interventions or treatments being tested.

Study design
This is an observational study with a planned enrollment of 40 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for the characterization of neuropathy index at 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04786977

Physiologic Measure of VIPN

Recruiting
Not specifiedAges 6–18Observational
Children's National Research Institute
~40 participants
Updated 2026-07-24 on ClinicalTrials.gov
What's tested:No Intervention, Observational Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Characterization of neuropathy index in patients with VIPN
Measured over 1 Year

Conditions

Chemotherapy-induced Peripheral Neuropathy

Explore related trials

Acute Lymphoblastic Leukemia

NCT04786977

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Children's National Health System

    Washington D.C., District of Columbiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Julia C Finkel, MD
[email protected]
(202)476-4867
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

6-18 years of age at the start of the study, are receiving vincristine in DI (clinical study population) and are willing and able to provide informed consent or assent to study participation.

Exclusion

have eye pathology which precludes pupillometry, are hemodynamically unstable, or are pregnant.

What this trial measures

  • Characterization of neuropathy index in patients with VIPN1 Year

    The primary objective of this study is the characterization of the neuropathy index in VIPN patients in order to measure VIPN severity.